Use of becaplermin in the closure of pharyngocutaneous fistulas

Head and Neck

Volumn 27, Issue 5, 2005, Pages 433-438

  Jakubowicz, David M ^a,b   Smith, Richard V ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Becaplermin; Complications; Laryngectomy, Regranex; Pharyngocutaneous fistula; Squamous cell carcinoma

Indexed keywords

BECAPLERMIN; BIOLOGICAL RESPONSE MODIFIER; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG EFFICACY; FEMALE; GRANULATION TISSUE; HEAD AND NECK CANCER; HUMAN; KERATINOCYTE; LARYNGECTOMY; MALE; PHARYNGOCUTANEOUS FISTULA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SKIN FISTULA; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; WOUND CLOSURE;

ADMINISTRATION, TOPICAL; AGED; ANTICOAGULANTS; CARCINOMA, SQUAMOUS CELL; CUTANEOUS FISTULA; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; PHARYNGEAL DISEASES; PLATELET-DERIVED GROWTH FACTOR; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; WOUND HEALING;

EID: 17844374056     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20182     Document Type: Article

References (19)

1. Non-healing wounds guidelines. [Madigan Army Base web site]. March 2002. Available at http://www.mamc.amedd. army.mil/Referral/guidelines/gensurg_wound. htm. Accessed March 30, 2004.
2. Bennett NT, Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 1993;165:728-737.
3. Somers T, Verbeken G, Vanhalle S, et al. Lysates from cultured allogeneic keratinocytes stimulate wound healing after tympanoplasty. Acta Oto-Laryngologica 1996;116:589-593.
4. Somers T, Duinslaeger L, Delaey B, et al. Stimulation of epithelial healing in chronic postoperative otorrhea using lyophilized cultured keratinocyte lysates. Am J Otol 1997;18:702-706.
5. Becaplermin. [FDA web site] December 16, 1997. Available at http://www.fda.gov/cber/biologics/products/becaomj121697.htm. Accessed March 2004.
6. Weiman JT, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo controlled double-blind study. Diabetes Care 1998;21:822-827.
7. Rees RS, Robson MC, Smiell JM, et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double blind, placebo-controlled trial. Wound Repair Regener 1999;7:141-147.
8. Yassur I, Hirschbein MJ, Karesh JW. 0.01% Becaplermin gel for the treatment of a chronic orbital ulcer after exenteration. Arch Ophthalmol 2001;119:1858-1859.
9. Hom DB, Manivel JC. Promoting healing with recombinant human platelet-derived growth factor-BB in a previously irradiated problem wound. Laryngoscope 2003;113:1566-1571.
10. Bello YM, Phillips TJ. Recent advances in wound healing. JAMA 2000;283:716-718.
11. Hingley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol 1995;132:79-85.
12. Petrazzuoli M, Goldsmith LA. Molecular mechanisms of cell signaling. In: Freedberg IM, editor. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill; 1999, p 115-131.
13. Bennett NT, Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 1993;165:728-737.
14. Pierce GF, Tarpley JE, Tseng T, et al. Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J Clin Invest 1995;96:1336-1342.
15. Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of becaplermin in the treatment of diabetic ulcers in four European countries. Pharmacoeconomics 2001;19:767-778.
16. Becaplermin package insert.
17. Oku K, Tanaka A, Yamanishi H, et al. Effects of various growth factors on growth of a cloned human esophageal squamous cancer cell line in a protein-free medium. Cancer Res 1991;11:1591-1596.
18. Shih SD, Rees TD, Miller EG, et al. The effects of platelet-derived growth factor-BB and insulin-like growth factor-1 on epithelial dysplasia. J Periodontol 1996;67:1224-1232.
19. Kallianinen LK, Hirshberg J, Marchant B, Rees RS. Role of platelet-derived growth factor as an adjunct to surgery in the management of pressure ulcers. Plast Reconstr Surg 2000;106:1243-1248.